Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
High dose 5‐ASA showed no clear difference in endoscopic recurrence compared with low dose 5‐ASA (moderate certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASA changes endoscopic recurrence compared with purine antimetabolites (very low certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with anti TNF‐ɑ (very low certainty).
1 finding from 1 review
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic recurrence · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether 5‐ASAs changes endoscopic recurrence compared with placebo (very low certainty).
1 finding from 1 review
Endoscopic relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes endoscopic relapse compared with anti TNF‐α (very low certainty).
1 finding from 1 review
Endoscopic relapse · people with surgically‐induced remission in Crohn's disease
Azathioprine or 6‐mercaptopurine showed no clear difference in endoscopic relapse compared with placebo (low certainty).
1 finding from 1 review
Endoscopic relapse · people with surgically‐induced remission in Crohn's disease
It is very uncertain whether azathioprine or 6‐mercaptopurine changes endoscopic relapse compared with 5‐aminosalicylic acid (very low certainty).
1 finding from 1 review
Endoscopic relapse · people with inflammatory bowel disease
It is very uncertain whether antidepressants changes endoscopic relapse at 12 months compared with placebo (very low certainty).
1 finding from 1 review
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Failure to maintain endoscopic remission · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Endoscopic response · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of 5‐point endoscopic response CDEIS · Patients with active Crohn's disease
Low dose naltrexone may leads to higher induction of 5‐point endoscopic response CDEIS compared with placebo (low certainty).
1 finding from 1 review
Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Adverse drug withdrawal events ‐ esophagitis (endoscopic findings) · people with moderate GERD and mild esophagitis, mean age 48 to 57 years
On‐demand deprescribing may leads to higher adverse drug withdrawal events ‐ esophagitis (endoscopic findings) compared with continued use (low certainty).
1 finding from 1 review
Adverse drug withdrawal events ‐ relapse (endoscopic findings) · people with mild to moderate esophagitis, symptomatic, aged > 18 years (mean age 73 years)
It is very uncertain whether abrupt discontinuation deprescribing changes adverse drug withdrawal events ‐ relapse (endoscopic findings) compared with continued use (very low certainty).
1 finding from 1 review
Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults with cancer receiving treatment
Granulocyte-colony stimulating factor (G-CSF) showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Intervention not reported
Minimally invasive step‐up approach: video‐assisted vs. endoscopic · people with necrotising pancreatitis
It is very uncertain whether the intervention changes minimally invasive step‐up approach: video‐assisted vs. endoscopic (very low certainty).
1 finding from 1 review
Intervention not reported
Minimally invasive step‐up approach: video‐assisted vs. endoscopic · people with necrotising pancreatitis
It is very uncertain whether the intervention changes minimally invasive step‐up approach: video‐assisted vs. endoscopic (very low certainty).
1 finding from 1 review